{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:15:06Z","timestamp":1787764506368,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00204-024-03763-w","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:02:18Z","timestamp":1715094138000},"page":"2541-2556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo"],"prefix":"10.1007","volume":"98","author":[{"given":"Julie","family":"Nilles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0575-184X","authenticated-orcid":false,"given":"Stephanie","family":"Ruez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"3763_CR1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","volume":"335","author":"AM Baciewicz","year":"2008","unstructured":"Baciewicz AM, Chrisman CR, Finch CK, Self TH (2008) Update on rifampin and rifabutin drug interactions. Am J Med Sci 335:126\u2013136. https:\/\/doi.org\/10.1097\/MAJ.0b013e31814a586a","journal-title":"Am J Med Sci"},{"key":"3763_CR2","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1016\/j.bmcl.2006.08.090","volume":"16","author":"J Barluenga","year":"2006","unstructured":"Barluenga J, Aznar F, Garc\u00eda A, Cabal M, Palacios JJ, Men\u00e9ndez M (2006) New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Bioorg Med Chem Lett 16:5717\u20135722. https:\/\/doi.org\/10.1016\/j.bmcl.2006.08.090","journal-title":"Bioorg Med Chem Lett"},{"key":"3763_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/mol.64.2.316","volume":"64","author":"Y Chen","year":"2003","unstructured":"Chen Y, Ferguson SS, Negishi M, Goldstein JA (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64:316\u2013324. https:\/\/doi.org\/10.1124\/mol.64.2.316","journal-title":"Mol Pharmacol"},{"key":"3763_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1124\/jpet.103.058818","volume":"308","author":"Y Chen","year":"2004","unstructured":"Chen Y, Ferguson SS, Negishi M, Goldstein JA (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308:495\u2013501. https:\/\/doi.org\/10.1124\/jpet.103.058818","journal-title":"J Pharmacol Exp Ther"},{"key":"3763_CR5","unstructured":"Committee for Medicinal Products for Human Use, European Medicines Agency, Guideline on the investigation of drug interactions, 2012, CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2**. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf (Accessed on 5 February 2024)"},{"key":"3763_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","volume":"62","author":"KE Dooley","year":"2013","unstructured":"Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Charles FC (2013) Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: Results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 62:21\u201327. https:\/\/doi.org\/10.1097\/QAI.0b013e318276cda9","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3763_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1046\/j.1432-1327.1999.00897.x","volume":"266","author":"M Duszenko","year":"1999","unstructured":"Duszenko M, Kang X, B\u00f6hme U, H\u00f6mke R, Lehner M (1999) In vitro translation in a cell-free system from Trypanosoma brucei yields glycosylated and glycosylphosphatidylinositol-anchored proteins. Eur J Biochem 266:789\u2013797. https:\/\/doi.org\/10.1046\/j.1432-1327.1999.00897.x","journal-title":"Eur J Biochem"},{"key":"3763_CR8","doi-asserted-by":"publisher","first-page":"12565","DOI":"10.1038\/s41598-020-69228-z","volume":"10","author":"SR Dyavar","year":"2020","unstructured":"Dyavar SR, Mykris TM, Winchester LC, Scarsi KK, Fletcher CV, Podany AT (2020) Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics. Sci Rep 10:12565. https:\/\/doi.org\/10.1038\/s41598-020-69228-z","journal-title":"Sci Rep"},{"key":"3763_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1124\/mol.105.013169","volume":"68","author":"SS Ferguson","year":"2005","unstructured":"Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA (2005) Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4\u03b1. Mol Pharmacol 68:747\u2013757. https:\/\/doi.org\/10.1124\/mol.105.013169","journal-title":"Mol Pharmacol"},{"key":"3763_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/archinte.162.9.985","volume":"162","author":"CK Finch","year":"2002","unstructured":"Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interactions: an update. Arch Intern Med 162:985\u2013992. https:\/\/doi.org\/10.1001\/archinte.162.9.985","journal-title":"Arch Intern Med"},{"key":"3763_CR11","first-page":"855","volume":"21","author":"AH Healan","year":"2017","unstructured":"Healan AH, Griffis JM, Proskin HM, O\u2019Riordan MA, Gray WA, Salata RA, Blumer JL (2017) Impact of rifabutin or rifampin on bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with heala thy adult volunteers. Antimicrob Agents Chemother 21:855\u2013917","journal-title":"Antimicrob Agents Chemother"},{"key":"3763_CR12","first-page":"1319","volume":"63","author":"DJ Horne","year":"2019","unstructured":"Horne DJ, Spitters C, Narita M (2019) Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Antimicrob Agents Chemother 63:1319\u20131419","journal-title":"Antimicrob Agents Chemother"},{"key":"3763_CR13","unstructured":"International council for harmonisation of technical requirements for pharmaceuticals for human use. ICH harmonized guideline Drug Interaction Studies M12. Available online: https:\/\/database.ich.org\/sites\/default\/files\/M12_Step1_draft_Guideline_2022_0524.pdf (Accessed on 5 February 2024)."},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/03602538109011084","volume":"12","author":"MT Kenny","year":"1981","unstructured":"Kenny MT, Strates B (1981) Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 12:159\u2013218. https:\/\/doi.org\/10.3109\/03602538109011084","journal-title":"Drug Metab Rev"},{"key":"3763_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/0091270003262807","volume":"44","author":"WK Kraft","year":"2004","unstructured":"Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA (2004) Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol 44:305\u2013313. https:\/\/doi.org\/10.1177\/0091270003262807","journal-title":"J Clin Pharmacol"},{"key":"3763_CR16","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1177\/009127009803801109","volume":"11","author":"M LeBel","year":"1998","unstructured":"LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vall\u00e9e F, Narang PK (1998) Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol 11:1042\u20131050. https:\/\/doi.org\/10.1177\/009127009803801109","journal-title":"J Clin Pharmacol"},{"key":"3763_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1385\/1-59259-838-2:207","volume":"290","author":"EL LeCluyse","year":"2005","unstructured":"LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, Richert L (2005) Isolation and culture of primary human hepatocytes. Methods Mol Biol 290:207\u2013229. https:\/\/doi.org\/10.1385\/1-59259-838-2:207","journal-title":"Methods Mol Biol"},{"key":"3763_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-2797(97)00071-9","volume":"107","author":"AP Li","year":"1997","unstructured":"Li AP, Reith MK, Rasmussen A, Gorski GC, Hall SD, Xu L, Kaminski DL, Cheng LK (1997) Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact 107:17\u201330","journal-title":"Chem Biol Interact"},{"key":"3763_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/10590501.2019.1639481","volume":"37","author":"D Li","year":"2019","unstructured":"Li D, Tolleson WH, Yu D, Chen S, Guo L, Xiao W, Tong W, Ning B (2019) Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 37:180\u2013214. https:\/\/doi.org\/10.1080\/10590501.2019.1639481","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/cpt.1073","volume":"104","author":"JD Lutz","year":"2018","unstructured":"Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, Worth A, Kearney BP, Mathias A (2018a) Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 1: Establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther 104:1182\u20131190. https:\/\/doi.org\/10.1002\/cpt.1073","journal-title":"Clin Pharmacol Ther"},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.1072","volume":"104","author":"JD Lutz","year":"2018","unstructured":"Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, Worth A, Kearney BP, Mathias A (2018b) Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 2: Prediction of decreased substrate exposure after rifabutin or carbamazepine. Clin Pharmacol Ther 104:1191\u20131198. https:\/\/doi.org\/10.1002\/cpt.1072","journal-title":"Clin Pharmacol Ther"},{"key":"3763_CR22","doi-asserted-by":"publisher","first-page":"16333","DOI":"10.1021\/bi0515570","volume":"44","author":"Y Morishima","year":"2005","unstructured":"Morishima Y, Peng H, Lin H-l, Hollenberg PF, Sunahara RK, Osawa Y, Pratt WB (2005) Regulation of cytochrome P450 2E1 by heat shock protein 90-dependent stabilization and CHIP-dependent proteasomal degradation. Biochem 44:16333\u201316340","journal-title":"Biochem"},{"key":"3763_CR23","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s00204-023-03531-2","volume":"97","author":"J Nilles","year":"2023","unstructured":"Nilles J, Weiss J, Sauter M, Haefeli WE, Ruez S, Theile D (2023) Comprehensive in vitro analysis evaluating the variable drug-drug interaction risk of rifampicin compared to rifabutin. Arch Toxicol 97:2219\u20132230. https:\/\/doi.org\/10.1007\/s00204-023-03531-2","journal-title":"Arch Toxicol"},{"key":"3763_CR24","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1124\/dmd.109.027680","volume":"37","author":"Y Pan","year":"2009","unstructured":"Pan Y, Gao W, Yu A (2009) MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37:2112\u20132117. https:\/\/doi.org\/10.1124\/dmd.109.027680","journal-title":"Drug Metab Dispos"},{"key":"3763_CR25","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/0006-2952(82)90671-2","volume":"31","author":"D Pessayre","year":"1982","unstructured":"Pessayre D, Larrey D, Vitaux J, Breil P, Belghiti J, Benhamou J (1982) Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. Biochem Pharmacol 31:1699\u20131704. https:\/\/doi.org\/10.1016\/0006-2952(82)90671-2","journal-title":"Biochem Pharmacol"},{"key":"3763_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1128\/AAC.45.2.502-508.2001","volume":"45","author":"RE Polk","year":"2001","unstructured":"Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Lou Y, Kristoff D, Stein DS (2001) Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 45:502\u2013508. https:\/\/doi.org\/10.1128\/AAC.45.2.502-508.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"3763_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s0092-8674(00)80314-1","volume":"90","author":"C Prodromou","year":"1997","unstructured":"Prodromou C, Roe SM, O\u2019Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP\/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65\u201375. https:\/\/doi.org\/10.1016\/s0092-8674(00)80314-1","journal-title":"Cell"},{"key":"3763_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1124\/dmd.113.052886","volume":"41","author":"A Ramamoorthy","year":"2013","unstructured":"Ramamoorthy A, Liu Y, Philips S, Desta Z, Lin H, Goswami C, Gaedigk A, Li L, Flockhart DA, Skaar TC (2013) Regulation of microRNA expression by rifampin in human hepatocytes. Drug Metab Dispos 41:1763\u20131768. https:\/\/doi.org\/10.1124\/dmd.113.052886","journal-title":"Drug Metab Dispos"},{"key":"3763_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0009-2797(99)00089-7","volume":"121","author":"B Reinach","year":"1999","unstructured":"Reinach B, Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R (1999) Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 121:37\u201348. https:\/\/doi.org\/10.1016\/S0009-2797(99)00089-7","journal-title":"Chem Biol Interact"},{"key":"3763_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/dmd.121.000638","volume":"50","author":"JP Savaryn","year":"2022","unstructured":"Savaryn JP, Sun J, Ma J, Jenkins GJ, Stresser DM (2022) Broad application of CYP3A4 liquid chromatography-mass spectrometry protein quantification in hepatocyte cytochrome P450 induction assays identifies nonuniformity in mRNA and protein induction responses. Drug Metab Dispos 50:105\u2013113. https:\/\/doi.org\/10.1124\/dmd.121.000638","journal-title":"Drug Metab Dispos"},{"key":"3763_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1124\/dmd.111.042275","volume":"40","author":"O Schaefer","year":"2012","unstructured":"Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, Atsushi SA, Ishiguro N, Matsumaru T, Terasaki T, Ebner T (2012) Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos 40:93\u2013103. https:\/\/doi.org\/10.1124\/dmd.111.042275","journal-title":"Drug Metab Dispos"},{"key":"3763_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf FH, Biebl MM, Buchner J (2017) The HSP90 chaperone machinery. Nat Rev Mol Cell Biol 18:345\u2013360. https:\/\/doi.org\/10.1038\/nrm.2017.20","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3763_CR33","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/17425255.2019.1648432","volume":"15","author":"C Sekaggya-Wiltshire","year":"2019","unstructured":"Sekaggya-Wiltshire C, Dooley KE (2019) Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opin Drug Metabo Toxicol 15:615\u2013618. https:\/\/doi.org\/10.1080\/17425255.2019.1648432","journal-title":"Expert Opin Drug Metabo Toxicol"},{"key":"3763_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0092-8674(00)80203-2","volume":"89","author":"CE Stebbins","year":"1997","unstructured":"Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90\u2013geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 89:239\u2013250. https:\/\/doi.org\/10.1016\/s0092-8674(00)80203-2","journal-title":"Cell"},{"key":"3763_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1023\/A:1026392429112","volume":"4","author":"WE Thasler","year":"2003","unstructured":"Thasler WE, Weiss TS, Schillhorn K, Stoll P, Irrgang B, Jauch K (2003) Charitable state-controlled foundation human tissue and cell research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 4:49\u201356. https:\/\/doi.org\/10.1023\/A:1026392429112","journal-title":"Cell Tissue Bank"},{"key":"3763_CR36","unstructured":"US Department of Health and Human Services, Food and Drug Administration. In vitro drug interaction studies- cytochrome P450 enzyme- and transporter-mediated drug interactions, guidance of industry. Available online: https:\/\/www.fda.gov\/media\/134582\/download (Accessed 5 February 2024)"},{"key":"3763_CR37","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1128\/AAC.06282-11","volume":"56","author":"M Vourvahis","year":"2012","unstructured":"Vourvahis M, Davis J, Wang R, Layton G, Choo HW, Chong C, Tawadrous M (2012) Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects. Antimicrob Agents Chemother 56:4303\u20134309. https:\/\/doi.org\/10.1128\/AAC.06282-11","journal-title":"Antimicrob Agents Chemother"},{"key":"3763_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106076","author":"J Weiss","year":"2022","unstructured":"Weiss J, Foerster KI, Weber M, Burhenne J, Mikus G, Lehr T, Haefeli WE (2022) Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound? Eur J Pharm Sci. https:\/\/doi.org\/10.1016\/j.ejps.2021.106076","journal-title":"Eur J Pharm Sci"},{"key":"3763_CR39","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1128\/AAC.01124-13","volume":"57","author":"B Williamson","year":"2013","unstructured":"Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A (2013) Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother 57:6366\u20136369. https:\/\/doi.org\/10.1128\/AAC.01124-13","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-024-03763-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T07:04:29Z","timestamp":1721891069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-024-03763-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1007\/s00204-024-03763-w","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}